Stay updated on Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page
- CheckyesterdayChange DetectedAdded a site-wide notice about a lapse in government funding and NIH Clinical Center status, and updated the page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check8 days agoChange DetectedGlossary display option added and metadata updated to Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0. The previous metadata items were renamed/removed to Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedA minor version update from v3.3.3 to v3.3.4 was applied; no visible changes to core page content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check44 days agoChange DetectedAdded a Locations section identifying Texas (Houston, MD Anderson Cancer Center) as a study site; removed the old Texas Locations entry and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check73 days agoChange DetectedThe page shows a new revision label (v3.3.2), replacing the previous label (v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check80 days agoChange DetectedThe government-funding/operating status notice was removed from the page. This notice previously informed users about NIH operations and potential delays.SummaryDifference0.3%

Stay in the know with updates to Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.